The Russian Direct Investment Fund (RDIF) said on Thursday that the Sputnik V coronavirus vaccine offers much higher protection against the Omicron variant than the Pfizer/BioNTech jab.
Citing comparative research at the Italian National Institute of Infectious Diseases Lazzaro Spallanzani, the RDIF noted that the number of antibodies two doses of Sputnik V create against Omicron is more than double compared to the antibodies the double dose of the Pfizer vaccine creates.
Earlier, studies showed that both vaccines offered low protection against Omicron, while Pfizer itself announced it is working on a new version of the jab that would target Omicron and expects to have it ready by March.
